Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$26.07
+0.0%
$25.32
$14.80
$40.47
$1.99B0.86837,857 shs694,133 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.32
+4.0%
$12.27
$8.02
$16.15
$6.83B1.675.24 million shs6.27 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$11.60
+1.8%
$11.08
$8.73
$13.06
$7.75B1.165.64 million shs6.02 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$37.48
-2.4%
$39.61
$29.17
$62.40
$7.15B1.11.56 million shs2.07 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
+0.04%-0.80%+2.16%-1.32%-14.58%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+3.96%+7.18%+8.45%+37.71%-20.34%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+1.75%+1.40%+7.81%+11.75%+9.74%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-2.42%-6.14%+1.38%+0.35%-2.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.1428 of 5 stars
4.51.00.00.01.70.80.0
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.5965 of 5 stars
1.32.00.00.31.41.71.3
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.6058 of 5 stars
3.53.00.00.02.62.50.0
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4.3229 of 5 stars
4.51.00.04.73.11.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
3.00
Buy$58.67125.04% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.50
Moderate Buy$15.175.95% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.00
Buy$17.5050.86% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$67.5880.32% Upside

Current Analyst Ratings Breakdown

Latest CGON, ROIV, RVMD, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/25/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
6/24/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$67.00 ➝ $73.00
6/24/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$57.00
6/18/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
6/17/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$52.00 ➝ $56.00
5/28/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
5/19/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $52.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/14/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$73.00 ➝ $72.00
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$1.14M1,743.03N/AN/A$9.63 per share2.71
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.60$2.34 per share6.11$12.33 per share1.16
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M271.46N/AN/A$7.45 per share1.56
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M602.88N/AN/A$13.47 per share2.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$88.04M-$1.51N/AN/AN/A-15,945.17%-16.71%-16.24%8/14/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7419.3416.082.698.43%7.54%3.57%8/6/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$600.09M-$4.00N/AN/AN/AN/A-37.06%-32.84%8/6/2025 (Estimated)

Latest CGON, ROIV, RVMD, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million
5/13/2025Q1 2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/7/2025Q1 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.12-$1.13-$0.01-$1.13N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
30.97
30.97
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
33.47
33.47
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/A
13.46
13.46

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
7.40%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
7.90%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6176.22 million70.58 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860679.81 million626.10 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.27 million170.99 millionOptionable

Recent News About These Companies

Revolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from Guggenheim
Revolution Medicines (NASDAQ:RVMD) Given Outperform Rating at Wedbush

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$26.07 +0.01 (+0.04%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$26.16 +0.09 (+0.35%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.32 +0.56 (+4.03%)
Closing price 06/26/2025 03:59 PM Eastern
Extended Trading
$14.34 +0.03 (+0.17%)
As of 05:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$11.60 +0.20 (+1.75%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$11.60 0.00 (-0.04%)
As of 06/26/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$37.48 -0.93 (-2.42%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$36.80 -0.68 (-1.81%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.